GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: DNDI-6510 is a non-covalent SARS-CoV-2 3C-like (main) protease (Mpro) inhibitor [2]. It was developed though leads produced via the open science COVID Moonshot project. Development was discontinued when it was discovered that DNDI-6510 promoted pregnane X receptor (PXR)-linked auto-induction of drug metabolism in mouse and rat in vivo, and in human hepatocyte cell lines.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Boby ML, Fearon D, Ferla M, Filep M, Koekemoer L, Robinson MC, COVID Moonshot Consortium‡, Chodera JD, Lee AA, London N et al.. (2023)
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science, 382 (6671): eabo7201. [PMID:37943932] |
2. Griffen EJ, Fearon D, McGovern BL, Koekemoer L, Balcomb BH, Szommer T, Fate G, Robinson RP, Lefker BA, Duberstein S et al.. (2025)
Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor. , Preprint. DOI: 10.1101/2025.06.16.660018 |